NCIt definition : An orally available cyclin-dependent kinase (CDK) inhibitor targets at cyclin D1/CDK4
and cyclin D3/CDK6 cell cycle pathway, with potential antineoplastic activity. Ribociclib
specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation.
Inhibition of Rb phosphorylation prevents CDK-mediated G1-S phase transition, thereby
arresting the cell cycle in the G1 phase, suppressing DNA synthesis and inhibiting
cancer cell growth. Overexpression of CDK4/6, as seen in certain types of cancer,
causes cell cycle deregulation.;
UNII : TK8ERE8P56;
InChIKey : RHXHGRAEPCAFML-UHFFFAOYSA-N;
CAS number : 1211441-98-3; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1211441-98-3
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;